G ammalinolenic acid (GLA;
3 18:3n6) is an essential fatty acid found in certain plant seed oils. It is metabolized to dihomogammalinolenic acid (DGLA; 20:3n6), the immediate precursor of PGE 1 , an eicosanoid with known antiinflammatory and immunoregulatory properties (1) (2) (3) (4) . GLA and DGLA also modulate immune responses in an eicosanoid-independent manner by acting directly on T lymphocytes (5-7). Administration of GLA reduces joint pain and swelling, as well as the need for nonsteroidal antiinflammatory drugs and corticosteroids in rheumatoid arthritis (RA) patients with active synovitis (8 -10) . Addition of GLA to cells in vitro or administration of GLA in vivo reduces secretion of IL-1␤ from LPS-stimulated human PBMC (11) .
IL-1␤ is an important mediator of inflammation and joint tissue injury, and it has become a target of therapy for patients with RA (12) . However, like most mediators, IL-1␤ also modulates cell function and participates in host defense (13, 14) . Thus, appropriate regulation of IL-1␤ production and secretion is necessary for prevention of excessive immune/inflammatory responses. The final biological effects of IL-1␤ depend on the balance between the different elements of the IL-1 system (pro-IL-1, converting enzyme, receptors, and receptor antagonist), most especially, perhaps, between IL-1␤ and IL-1R antagonist (IL-1Ra). Pro-IL-1␤ is a 35-kDa molecule that is converted by the action of IL-1-converting enzyme (ICE, now referred to as caspase-1) to a 17-kDa "mature" IL-1␤, which is the biologically active compound secreted by monocytes (14) . Peripheral blood monocytes (PBM) from RA patients exhibit increased production of IL-1␤ compared with cells from normal subjects and patients with osteoarthritis (15) . Synovium from RA patients is characterized by an imbalance between IL-1␤ and IL-1Ra production, in favor of IL-1␤ (16) . In the studies presented here, mechanisms whereby GLA modulates IL-1␤ secretion were investigated in isolated PBM stimulated with either LPS or by IL-1 itself. LPS stimulates an initial increase in IL-1␤ production and secretion, which in turn induces further IL-1␤ production, an amplification system termed autoinduction (17) . We show here in experiments with human cells in vitro that GLA reduces mainly autoinduction of IL-1␤ in LPS-stimulated cells.
Materials and Methods

Cell isolation and stimulation
Mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers and of patients with RA using Ficoll-Hypaque separation. Monocytes (PBM) were isolated by adherence in 24-well tissue culture plates. Adherent cells were washed, and cells were maintained overnight at 37°C, 5% CO 2 , in RPMI 1640 2% autologous serum. Cells were washed again, medium was replaced, and experiments were performed with the rested cells (18) . Cells were treated or not with GLA for 60 min and then stimulated with either 10 ng/ml LPS or 1 ng/ml recombinant human IL-1␣ for 4 h (for mRNA determination in cells) or 18 h (for IL-1␤ assay in supernatants).
Research Center, Cincinnati, OH). RNA was purified according to manufacturer's instructions. Cells were homogenized by allowing the lysed samples to incubate at room temperature for 10 min, and then 200 ml of chloroform was added and samples were extracted. The aqueous phase was removed to new tubes, 500 ml of isopropanol was added, and samples were incubated at room temperature for 15 min. Samples then were centrifuged for 15 min at full speed in an Eppendorf model 5415c centrifuge (Eppendorf Scientific, Westbury, NY) to precipitate the RNA. Supernatant fluid was withdrawn and pellets were washed with 75% ethanol and centrifuged. Supernatants were withdrawn again, and pellets were allowed to air dry for 5 min. Probe generation. A probe template set consisting of templates for the genes of interest and housekeeping genes L32 and GAPDH (BD PharMingen, San Diego, CA) were biotin labeled. A mixture consisting of 1 l of the template set, 2 l of biotin labeling mix (Boehringer-Mannheim, Indianapolis, IN), 2 l of DTT, 4 l of 5ϫ transcription buffer, 1 l of RNaisin, 1 l of T7 polymerase, and 9 ml of water (all components of mixture with the exception of the biotin labeling mix are from the BD PharMingen in vitro transcription kit) was mixed and then incubated at 37°C for 1 h. DNase (20 l) was added and the reaction mixture was incubated at 37°C for an additional 30 min. EDTA (26 l of 20 mM), 25 l of Tris-saturated phenol (Sigma, St. Louis, MO), 25 l of chloroform/ isoamyl alcohol (50:1), and 2 l of yeast tRNA were added. The mixture was vortexed to emulsion and microcentrifuged at full speed for 5 min. The aqueous phase was removed to a new tube, and 50 l of chloroform/ isoamyl alcohol (50:1) was added. Subsequent to extraction, the aqueous phase was removed to a new tube, and 50 l of 4 M ammonium acetate was added with 250 l of ethanol. This mixture was incubated at Ϫ80°C for a minimum of 30 min and microcentrifuged at full speed at 4°C for 15 min. The supernatant was removed, and 100 l of cold 90% ethanol added, followed by centrifugation at 4°C for 5 min. Subsequent to removal of all fluid, the pellet was allowed to air dry for 5 min. The labeled probe was dissolved in 50 l of hybridization buffer.
RNase protection assay
RNA was dissolved in 18 l of hybridization buffer, and 2 l of a 1/1 dilution of probe was added to each RNA sample. The assay was conducted with a BD PharMingen RNase protection assay kit according to the manufacturer's instructions. Subsequent to electrophoresis, RNA was transferred to a positively charged nylon membrane with a SemiPhor semidry transfer device (Hoeffer Scientific Instruments, San Francisco, CA). The membrane was UV-cross-linked in a Stratalinker (Stratagene, Palo Alto, CA) for 5 min. The membrane then was incubated with constant motion in blocking buffer for at least 1 h. Next, the membrane was incubated with Avidx-AP (Tropix, Bedford, MA) 1:20,000 in blocking buffer with constant motion for 30 min. The membrane then was washed five times for 10 min each in washing buffer. The membrane then was blotted on absorbent paper until damp, and placed into a plastic sleeve. CDP-Star RTU (Tropix) was added to cover the membrane entirely. The membrane was incubated at room temperature for 5 min, blotted to remove excess CDP-Star, placed in a new plastic cover, and exposed to film. Densitometry was conducted by scanning an image of the membrane into the NIH Image program (National Institutes of Health, Bethesda, MD). All reported levels are normalized for GAPDH levels.
Stability of pro-IL-1␤ mRNA
To investigate whether steady-state levels of pro IL-1␤ mRNA are altered by changing its stability, new transcription was arrested by addition to cells of 5 g/ml actinomycin D 4 h after stimulation. Steady-state mRNA levels were assayed at intervals to determine decay of mRNA. Experiments in which 50 g/ml cyclohexamide also was added to halt new protein synthesis were performend in a similar manner. Cytoplasmic RNA was obtained by a modification of the method of Borun et al. (20) . Cells suspended in 1.5 ml of cold PBS were pelleted (microcentrifuged at full speed for 15 s) and then washed in cold PBS. Pellets were resuspended in 45 l of cold Tris-EDTA (10 M Tris and 1 M EDTA), 5 l of 5% Nonidet P-40 was added, and the samples were placed on ice for 5 min. An additional 5 l of 5% Nonidet P-40 was added and the mixture was microcentrifuged for 2.5 min at full speed. Supernatants (50 l) were transferred to tubes containing a fresh mixture of 30 l 20ϫ SSC and 20 l of formaldehyde. These tubes were incubated at 60°C for 15 min and were either blotted directly to a positively charged nylon membrane with a dot blot device or were stored at Ϫ80°C for future blotting. The amount of RNA blotted was normalized for the number of cells harvested.
After blotting, the membrane was UV-cross-linked for 5 min in a UV Stratalinker. The membrane then was blocked with a hybridization buffer, which consisted of: 50% formamide, 5ϫ SSC, 0.1% sarcosyl, 0.02% SDS, 2% blocking buffer, and 0.2% salmon sperm DNA for 1 h at 42°C. A biotin-labeled probe for IL-1␤ was added to 10 ml of hybridization buffer, boiled for 10 min, and added to the membrane. The membrane was maintained with motion overnight at 42°C. The membrane then was subjected to a series of washes in reagents provided in the digoxigenin wash and block buffer was set according to the manufacturer's instructions, with the exceptions that the reagent used in this protocol was AvidX-AP at a dilution of 1/20,000 in 1ϫ blocking buffer and the luminescent reagent was CDP Star (Tropix). The treated blot then was exposed to Kodak XAR film (Eastman-Kodak, Rochester, NY).
Statistical analysis
Data were analyzed and compared by paired Student's t test.
Results
Cell isolation
When freshly isolated monocytes were cultured in polypropylene tubes and were used as soon as they adhered to plates, variable amounts of IL-1␤ secretion were observed in the absence of cell stimulation. However, when cells were cultured in polystyrene plates overnight, background levels of IL-1␤ were low and induction of IL-1␤ and effects of GLA were consistent. Thus, the mean Ϯ SD secretion of IL-1␤ from freshly isolated cells was 940 Ϯ 670 pg/ml (n ϭ 4), whereas the baseline level of IL-1␤ secreted from cells first cultured in polystyrene plates overnight was 48.8 Ϯ 24 pg/ml (n ϭ 5).
Separation of LPS induced from IL-1 induced IL-1␤ secretion
Because LPS-induced IL-1␤ includes IL-1 induced by LPS and further IL-1 induction by IL-1␤ (autoinduction), we separated LPS-induced IL-1␤ from autoinduction by pretreating LPS stimulated cells with IL-1Ra. A 100-fold excess of IL-1Ra to IL-1␣ (100 ng/ml IL-1Ra added to cells stimulated with 1 ng/ml IL-1␣) completely prevented secretion of IL-1␣-induced IL-1␤ (Fig. 1A) , whereas IL-1␤ secretion from PBM exposed to 100 ng/ml IL-1Ra and stimulated with LPS was reduced by 38.9% (Fig. 1B) . Thus, in the experiment shown, LPS stimulation accounted for 61.1% of IL-1␤ secretion, and the remaining 38.9% of IL-1␤ secretion was attributable to autoinduction. This ratio of LPS induced to autoinduced IL-1␤ varies from donor to donor.
Influence of GLA on IL-1␤ secretion
We then determined the effect of GLA on LPS-induced IL-1␤ secretion from cells first treated with IL-1Ra and on IL-1␣-induced IL-1␤ secretion (simulated autoinduction). Addition of GLA in vitro reduced secretion of IL-1␤ in a dose-dependent manner.
However, GLA reduced IL-1␤ secretion much more effectively when cells were stimulated by IL-1␣ than when they were stimulated by LPS (Fig. 2) . In a series of experiments, a 10 g/ml concentration of GLA reduced LPS-induced IL-1␤ secretion by 37.9 Ϯ 10.7% (mean Ϯ SD; n ϭ 9; p Ͻ 0.01 vs untreated control cells). In contrast, treatment of cells with 10 g/ml GLA reduced IL-1␣-induced IL-1␤ secretion by 61.5 Ϯ 19.3% (mean Ϯ SD; n ϭ 6; p Ͻ 0.01 vs untreated control cells).
Effect of GLA on pro-IL-1␤ gene expression
Concentrations of GLA that reduced LPS-induced IL-1␤ secretion (Fig. 2) did not reduce pro-IL-1␤ mRNA (Figs. 3 and 4) . However, GLA did reduce IL-1-induced pro-IL-1␤ mRNA markedly (Figs. 3  and 4) . The observation suggests further that the GLA effect on IL-1␤ secretion was on autoinduction rather than on the initial LPS-induced IL-1␤ production.
Pro-IL-1␤ mRNA stability
The different effects of GLA on steady-state levels of LPS and IL-1-induced pro-IL-1␤ mRNA were not attributable to an influence on mRNA stability as determined by the change in cellular message content after cells were treated with actinomycin D to stop transcription. GLA did not change pro-IL-1␤ mRNA stability whether cells were stimulated with LPS (Fig. 5, A and C) or IL-1␣ (data not shown). However, when protein synthesis was inhibited by cycloheximide in addition to inhibition of transcription by actinomycin D, a difference in mRNA stability between untreated and GLA treated cells emerged (Fig. 5, B and D) . In GLA-treated cells (Fig. 5D) , stability of the pro-IL-1␤ message was reduced markedly (53% remaining after 16 h; t 1/2 ϭ 17.1 h) compared with untreated cells (94% remaining after 16 h; t 1/2 ϭ 128.9 h). The data shown in Fig. 5 , A and D suggest that GLA treatment induced a protein that reduced pro-IL-1␤ mRNA stability.
Washout studies
To determine whether the continuous presence of GLA in the stimulated cell cultures was required for the inhibitory activity, washout studies were done in which PBM were treated with GLA for 1 h and then washed extensively and further incubated with LPS or IL-1␣ alone for 18 h. The results (Table I) show that GLA had to be present continuously to suppress IL-1␤ secretion.
Experiments with cells from patients with RA
In general, PBM from RA patients are more activated than PBM from controls (15) . Nonetheless, the differential effects of GLA on LPS-induced and autoinduced IL-1␤ secretion also were seen in PBM from RA patients ( Fig. 6 and Table II) . In these experiments, autoinduction of IL-1␤ (as simulated by stimulation with IL-1␣) was blocked by incubation of cells with 100 ng/ml of IL-1Ra before stimulation with LPS. Results of the experiment with cells from a 61-year-old woman with an 8-year history of RA (Fig. 6A) indicate that 52.0% of LPS-induced IL-1␤ secretion was attributable to LPS alone (IL-1Ra plus LPS: autoinduction blocked). This portion of IL-1␤ secretion was not reduced by addition to cells of GLA (IL-1Ra plus LPS plus GLA). IL-1␤ induced by LPS was reduced 50.6% (LPS plus GLA). Responses (documented in Fig. 6 and Table II) varied among the four RA patients.
Discussion
The results of the experiments presented here indicate that GLA has the capacity to influence IL-1␤ production and secretion and thereby modulate its biological activity. Joint tissue injury in RA patients appears attributable in large part to activation of mononuclear cells and synovial cells with subsequent release of IL-1␤ and other cytokines (21) . Interference with production and action FIGURE 2. Effect of GLA on IL-1␤ secretion from cells stimulated with 10 ng/ml LPS or 1 ng/ml recombinant human IL-1␣. LPS-stimulated PBM (2 ϫ 10 6 ) were treated first for 30 min with 100 ng IL-1Ra, then 60 min with GLA. IL-1␣-stimulated cells were treated first for 60 min with GLA. Experimental protocol and assays were performed as outlined in Materials and Methods. of these polypeptide mediators of inflammation has emerged as a major strategy for treatment of RA patients (12) .
The addition of GLA to PBM in vitro reduces release of IL-1␤ from LPS-stimulated cells, but GLA does not influence steadystate pro-IL-1␤ mRNA levels, suggesting that GLA affects a process that occurs after LPS induces an initial production of IL-1␤. One such event, which contributes to total secretion of IL-1␤ from LPS-stimulated cells, is the subsequent autoinduction of pro-IL-1␤ production by the IL-1␤ initially secreted (22) . Treatment of cells with IL-1Ra before stimulation with LPS prevents autoinduction and separates LPS-induced from autoinduced IL-1␤. The addition of GLA reduces markedly IL-1␤ autoinduction as simulated by IL-1␣ stimulation. In contrast, GLA reduces the LPS-induced portion of IL-1␤ release modestly, as illustrated by experiments using exogenous IL-1Ra to block autoinduction. Donor cell variability is reflected in the amount of IL-1␤ secreted in response to cell stimulation, the response to GLA, and the proportion of LPS-induced IL-1␤ secretion that is due to autoinduction. In general, autoinduction accounted for ϳ40% of total IL-1␤ secretion. Our studies confirm others, which indicate that self-induction of IL-1 contributes significantly to IL-1␤ synthesis in stimulated human monocytes (23) .
Variability of responses appears to be even greater among patients with RA ( Fig. 6 and Table II) . It is not clear whether these cellular responses will predict clinical responses to treatment with GLA. If they do, we would predict that patients C and D (Table II) , whose cells exhibit prominent autoinduction of IL-1, will respond FIGURE 4. GLA reduces IL-1␣-induced but not LPS-induced pro-IL-1␤ mRNA in human PBM. In this experiment, cells were treated with 10 g/ml GLA. Experimental protocol was performed as in Fig. 2 . A, Pro-IL-1␤ mRNA was analyzed by RNase protection assay. B, Densitometry values were obtained by scanning the membrane (A and B) into the NIH Image program. All values were normalized for GAPDH levels. well to GLA, whereas patient B, in whom autoinduction is minimal, will not respond well clinically to GLA.
The host defense properties of IL-1 include reduction of mortality from bacterial and fungal infections in animals. Administration of IL-1 to humans increases the number of bone marrow precursor cells and circulating platelets and neutrophils. However, increasing doses cause fever, gastrointestinal disturbances, myalgia, arthralgia, and hypotension (14) . It is possible that an initial insult to the cell provokes a protective burst of IL-1 and that the amplification system (autoinduction) is a backup defense mechanism. If in endotoxic shock or in diseases characterized by chronic inflammation, autoinduction of IL-1 is not well regulated, the excessive activity of IL-1␤ would then be pathological rather than protective. Among similar patients who suffer similar bacterial infections, some survive while others succumb to shock and multiple organ failure (24) , perhaps due to different genetic predispositions to exuberant inflammation. Proper regulation of IL-1 autoinduction may be one component of an appropriate response to LPS and other stimuli.
We have shown (25) that GLA alters the cascade that transduces signals from plasma membrane to nucleus during activation of human T lymphocytes. The signaling pathways leading to IL-1␤ production after stimulation of human PBM with LPS and IL-1 have not been characterized fully. It does appear that the pathways diverge. Although both LPS and IL-1␤ initiate a broad range of signaling cascades, several of which may influence IL-1␤ production (26), IL-1 initiates a more narrow spectrum of cascades that leads to production of IL-1␤ (27) . For example, p38 mitogen-activated protein kinase is needed for successful induction of IL-1␤ by LPS (28) , but the enzyme is not necessary for IL-1 induction of FIGURE 6. Experiments with PBM from patients with RA. LPS, Cells stimulated with 10 ng/ml LPS for 18 h. Mean release of IL-1␤ from unstimulated cells ϭ 91 pg/ml. LPS ϩ GLA, Cells treated with 10 g/ml GLA for 60 min before stimulation with LPS. IL-1Ra ϩ LPS, Cells treated with 100 ng/ml IL-1Ra for 60 min before LPS stimulation (autoinduction blocked). IL-1Ra ϩ GLA ϩ LPS, Cells treated with 100 ng/ml IL-1Ra 60 min, then 10 g/ml GLA 60 min, then LPS. A-D, Cells from four different RA patients (see Table II ). IL-1␤ (29) . It is likely that one or more of the redundant pathways activated by LPS are not affected by GLA. It is possible that GLA influences signal transduction pathways through an effect on peroxisome proliferator-activated receptors (PPARs). PPARs, intracellular receptors that act as transcription factors and mediate ligand-dependent transcriptional activation and repression (30) , are cellular receptors for long chain fatty acids, including GLA (31). It will be important to compare in detail the varied LPSand IL-1-induced signaling pathways in an effort to better understand regulation of the amplification of IL-1␤ production observed in chronic inflammation and, even more tragically, in septic shock.
Another potential mechanism whereby GLA might reduce IL-1 autoinduction is suggested by the observations of pro-IL-1␤ mRNA stability illustrated in Fig. 5 . In these experiments, inhibition of translation by cycloheximide in actinomycin D-treated, LPS-stimulated cells results in stability of pro-IL-1␤ message that is greater than in LPS-stimulated cells treated with actinomycin alone, in which transcription is halted and translation proceeds (Fig. 5, B vs A) . These observations suggest that a protein synthesized de novo upon LPS stimulation leads, directly or indirectly, to destabilization of pro-IL-1␤ mRNA, or that translation itself leads to destabilization of the message. When transcription is stopped in GLA-treated cells and translation proceeds, pro-IL-1␤ mRNA is degraded as it is in cells not treated with GLA (Fig. 5, C vs A) , and GLA does not appear to alter pro-IL-1␤ mRNA stability. However, when translation is stopped by cycloheximide, the innate stability of the pro-IL-1␤ mRNA is observed (Fig. 5B) . In GLAtreated cells in which translation is stopped, the instability of mRNA induced by GLA, unrelated to the translation of this specific pro-IL-1␤ mRNA (translation of which has been stopped by the cycloheximide), is revealed (Fig. 5D) . The observation suggests that GLA induces a protein that destabilizes (accelerates decay of) pro-IL-1␤ mRNA. If GLA is indeed destabilizing message induced by LPS, then it is possible that by the time the LPSinduced IL-1 is ready to induce (autoinduce) further IL-1␤ production, the pro-IL-1␤ mRNA is too unstable to support transcription. That GLA reduces LPS-induced pro-IL-1␤ mRNA 20 h after cells are stimulated but not at 4 h after stimulation (data not shown) also suggests that possibility.
Although the biological activity of IL-1␤ is mainly extracellular, the protein lacks a secretory signal sequence (32) . IL-1␤ is synthesized by monocytes as a 35-kDa precursor (pro-IL-1␤) that accumulates in the cytosol (33) and is proteolytically processed to the mature 17-kDa IL-1␤ by the IL-1␤-converting enzyme caspase-1 (34) . In LPS-activated human monocytes, IL-1␤ is contained in endolysosomes, exocytosis of which leads to extracellular release of the cytokine (35) . Although it appears that the major mechanism whereby GLA reduces secretion of IL-1␤ from LPS-stimulated cells is by reduction of autoinduction, an effect on secretion itself is not excluded by our studies. Increases in cellular concentrations of cAMP result in reduced secretion of lysosomal products from activated human neutrophils (36) , and DGLA increases cAMP in human synovial cells (2) . Thus, the ability of GLA to alter IL-1␤ secretion directly needs to be addressed.
These studies suggest that GLA, an unsaturated fatty acid with the ability to reduce active synovitis in patients with RA, may exert its therapeutic effects, at least in part, by modulation of IL-1␤ secretion from activated cells. GLA does not interfere significantly with production of IL-1␤ due to LPS stimulation, but does suppress the secondary, autoinduced (IL-1-induced) stimulation of IL-1␤ production. It is possible that dysregulation of the amplification process known as autoinduction leads to unrestrained inflammation in genetically predisposed individuals.
